Mark M. Kowalski
Director Técnico/Científico/I+D en EUPRAXIA PHARMACEUTICALS INC. .
Fortuna: 22 800 $ al 30/04/2024
Cargos activos de Mark M. Kowalski
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
EUPRAXIA PHARMACEUTICALS INC. | Director Técnico/Científico/I+D | 18/05/2023 | - |
Historial de carrera de Mark M. Kowalski
Antiguos cargos conocidos de Mark M. Kowalski.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SIERRA ONCOLOGY, INC. | Director Técnico/Científico/I+D | 01/01/2017 | 10/03/2022 |
ARBUTUS BIOPHARMA CORPORATION | Director Técnico/Científico/I+D | 12/08/2013 | 30/09/2016 |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Director Técnico/Científico/I+D | - | - |
AAIPharma, Inc.
AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Director Técnico/Científico/I+D | - | - |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Director Técnico/Científico/I+D | - | - |
Consejero General | - | - | |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Director Técnico/Científico/I+D | 17/01/2011 | - |
Consejero General | 17/01/2011 | - |
Formación de Mark M. Kowalski.
Rutgers State University of New Jersey | Undergraduate Degree |
University of Kansas Medical School | Doctorate Degree |
Estadísticas
Internacional
Canadá | 5 |
Estados Unidos | 5 |
Francia | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 7 |
General Counsel | 2 |
Undergraduate Degree | 1 |
Sectorial
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
ARBUTUS BIOPHARMA CORPORATION | Health Technology |
EUPRAXIA PHARMACEUTICALS INC. | Health Technology |
Empresas privadas | 5 |
---|---|
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
AAIPharma, Inc.
AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Commercial Services |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Health Technology |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Mark M. Kowalski
- Experiencia